With the US in regulatory limbo, Europe is winning the race to be the first regulated drugs market to approve generic copies of biotech drugs - despite the protests of the biotech pioneers who created them.
Erythropoietin is a hot candidate biogenerics companies (picture courtesy Flamel Technologies)
The pioneers of the biotech industry get a last chance to defend their products against imitators at a meeting in Paris today and...
This page requires a Science|Business Network Membership
This page is available to Science|Business Network Members only. If you are already a member then please log in (above).
Note if you are only registered to receive our Bulletin, or have previously purchased an item from our store, this does not give you access to the full benefits of the site. Join Now and plug into the Science|Business Network to get full access to all our news, events and business opportunities.
Science|Business is the first independent media company that brings together researchers, investors and policy makers in the European innovation community. It does so with a top-quality team and unique network of Europe's leading scientific institutions, corporations, policy makers and IP and VC specialists.
Be where innovation begins – become a member. Click here to learn more.